Antagonism of eosinophil adhesion in asthma

Research output: Contribution to journalArticle

Abstract

There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and ß2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise, the problems and successes regarding recent patents and developments in adhesion-based therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.
Original languageEnglish
Pages (from-to)210-213
Number of pages4
JournalRecent Patents on Inflammation & Allergy Drug Discovery
Volume4
Issue number3
DOIs
Publication statusPublished - 1 Nov 2010

Fingerprint

Eosinophils
Asthma
Inflammation
Transendothelial and Transepithelial Migration
Selectins
Patents
Vascular Cell Adhesion Molecule-1
Immunologic Factors
Cell Adhesion Molecules
Intercellular Adhesion Molecule-1
Chemokines
Integrins
Cytokines
Lung
Therapeutics

Cite this

Antagonism of eosinophil adhesion in asthma. / Walsh, Garry M.

In: Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 4, No. 3, 01.11.2010, p. 210-213.

Research output: Contribution to journalArticle

@article{2a8a2d428a6f4dc4804e679284cf8ea9,
title = "Antagonism of eosinophil adhesion in asthma",
abstract = "There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and {\ss}2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise, the problems and successes regarding recent patents and developments in adhesion-based therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.",
author = "Walsh, {Garry M}",
year = "2010",
month = "11",
day = "1",
doi = "10.2174/187221310793564263",
language = "English",
volume = "4",
pages = "210--213",
journal = "Recent Patents on Inflammation & Allergy Drug Discovery",
issn = "1872-213X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Antagonism of eosinophil adhesion in asthma

AU - Walsh, Garry M

PY - 2010/11/1

Y1 - 2010/11/1

N2 - There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and ß2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise, the problems and successes regarding recent patents and developments in adhesion-based therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.

AB - There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and ß2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise, the problems and successes regarding recent patents and developments in adhesion-based therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.

U2 - 10.2174/187221310793564263

DO - 10.2174/187221310793564263

M3 - Article

VL - 4

SP - 210

EP - 213

JO - Recent Patents on Inflammation & Allergy Drug Discovery

JF - Recent Patents on Inflammation & Allergy Drug Discovery

SN - 1872-213X

IS - 3

ER -